hitherto known compound." This high selectivity for HSV inhibition appears to be due. to the fact that HSV thymidine kinase specifically phosphorylates ACG, whereas normal cell thymidine kinase does not signiicantly (3). ACG does not appear to be metabolized or substantially modified when given to normal mice, rats, or dogs (P. de 65, 1978) in contrast to other antiviral compounds. Several recent reports have shown that ACG is highly effective in the treatment of herpetic infections in experimental animals (9, 11) and humans (4, 5) . Except for the use of known thymidine kinasedeficient mutant strains of HSV by Elion In this paper we present observations conceming: (i) the generation of HSV resistance to ACG by exposure ofvirus to increasing concentrations of the drug in vitro; (ii) the refractility of corneal lesions, experimentally induced by an ACG-resistant strain of HSV, to drug treatment; (iii) wide variations in the susceptibilities of naturally occurring, recently isolated, and laboratory strains of HSV to ACG; and (iv) the susceptibility cross-resistance pattern of an ACG-resistant HSV strain to iododeoxyuridine (IUDR) and adenine arabinoside (Ara-A).
MATERIALS AND METHODS
Cell cultures. Viruses were grown and titrated at 36°C in human fetal fibroblasts derived from fetal tissues in our laboratory and used for virus work before the fifth passage. Cells were grown and maintained in basal medium Eagle (BME; Auto-Pow, Flow Laboratories) supplemented with 0.112% sodium bicarbonate, 2 mM L-glutamine (GIBCO Laboratories, Grand Island, N.Y.), 2 mg of neomycin (Mycifradin sulfate, Upjohn Co.) per 100 ml and 5 to 20% calf serum (KC Biologicals Inc., Lenexa, Kans.). Five percent BME, as described hereafter, would indicate medium containing 5 ml of calf serum in a total volume of 100 ml. tesy of Hubert Malherbe); (ii) HSV-2 strains Benefield (courtesy of Amos Palmer), G (American Type Culture Collection, Rockville, Md.), EL 1, EL 3, EL 4, EL 6, and EL 7 (clinical isolates).
Viral plaque titrations. The titer of all HSV strains was determined by a plaque titration method (12) . Tissue culture dishes (35 by 10 mm, Falcon) were seeded with cells and used for assays when they were approximately 75% monolayer. Volumes (0.2 ml) of logarithmic dilutions of each virus strain were inoculated onto each of two tissue culture dishes and adsorbed for 1 h with intermittent shaking, the inoculum was removed, and 2 ml of 5% BME containing 0.5% human immune serum globulin (USP Immuglobin, Travenol Laboratories Inc., Costa Mesa, Calif.) was added. After a 48-h incubation period at 36°C in a 5% CO2 atmosphere, the overlay medium was removed, and the cell sheets were stained with a 0.05% aqueous crystal violet solution. The number of plaques was counted with a Nikon profile projector which magnified the dishes lOx. The duplicates were averaged, and the number of plaque-forming units was calculated. freshly by dissolving 2.11 mg in 0.5 ml of 0.1 N NaOH and adding 9.5 ml of 5% BME. The IUDR stock solution was prepared by dissolving 1 g of IUDR in 10 ml of dimethyl sulfoxide and storing small portions in the dark at -20°C. The Ara-A stock solution was prepared by dissolving 10 mg of Ara-A in 1 ml of dimethyl sulfoxide. Appropriate dilutions of each drug were made in 5% BME containing 0.5% human immune serum globulin just before usage. For 50% effective dose (ED50) titrations, all titrations were done at least in duplicate. Tissue culture dishes (35 by 10 mm) with approximately 75% cell monolayer were inoculated with approximately 50 plaque-forming units of HSV per 0.2 ml, and the virus was adsorbed for 1 h, with intermittent shaking. After removal of the inoculum, 2 ml of 5% BME with 0.5% immune globulin and threefold dilutions of the appropriate drug were added. One set of dishes received no drug and was later used for the "no-drug control." After a 48-h incubation period at 36°C in a 5% CO2 atmosphere, the overlay medium was removed, the cells were stained as described above, and plaques were counted. After averaging the counts of replicate plates, the number of plaques emerging in the presence of each drug dilution was calculated as a percent of the control as follows: (average number of plaques with drug/average number of plaques without drug) x 100. Each drug titration was plotted on semi-logarithmic graph paper. The ED5o concentration was that amount of drug per milliliter of overlay medium that inhibited the plaque numbers by 50%, compared with the nodrug controls, and this was read off the graphic plot of the data.
Drug studies in HSV-infected rabbit eyes.
Adult New Zealand white rabbits were used through- Rabbits were inoculated with the appropriate drugsusceptible or drug-resistant virus; on either day 3 or 4 of infection (depending on the experiment), their eyes were stained with a 1% aqueous solution of bengal rose and examined with slit-lamp illumination by one of us (R.H.P.) in single-masked fashion. The lesions were scored from 0 to 5, according to severity. On day 3 or 4, animals inoculated with a given virus were divided into two equal groups, the groups being selected to have almost identical average lesion scores; one group of animals was then used for ACG treatment, and the other received placebo treatment. Ointment was applied into the eyes four times per day through either day 9 or 10 of viral infections. Ophthalmic lesions were scored periodically as described above. Five to seven animals were used in each group, giving a total of 10 to 14 infected eyes for evaluation in each experiment. The mean lesion score for each treatment group was calculated at each observation time and plotted graphically (see Fig. 3 and 4) .
RESULTS
Emergence of ACG-resistant virus in vitro. During the course of determining inhibitory concentrations of ACG with various laboratory strains of HSV, we observed that a few plaques of Patton strain HSV-1 emerged in the presence of 9 to 27 umol of ACG (see Fig. 1A ). However, no plaques formed in the presence of drug concentrations greater than 27 ,umol. This HSV-1 strain was serially passaged through increasing concentrations of ACG (6, 18 , and 54 ,umol of ACG, respectively). The emerging virus was then passaged twice more through 54 ,umol of ACG, divided in small volumes, and stored at -700C. This virus was found to produce cytopathic effects rapidly, to have a titer of 3.2 x 107 plaque-forming units per ml and to show complete in vitro resistance to 162 umol of ACG (see Fig. 1B Fig. 3 , strain produced corneal lesions wh most completely refractory to tree 1% unguent ACG (on day 7, the av scores were 3.6 and 3.7 for ACGplacebo-treated eyes). Lesions indi original strain responded well to thl treatment (lesion scores in placebc treated animals on day 7 were 4.3 spectively).
A second experiment was designeo begin treatment 1 day earlier and (i unguent ACG instead of 1%. The shown in Fig. 4 .I3pe strains and produced by the resistant strain were somewhat aces between better controlled by ACG treatment than in ms, particu-experiment 1. Again, lesions induced by the orig-1 to 10 ,umol inal strain responded well to treatment. It appears, therefore, that starting therapy 1 day rabbits by earlier and using 3% rather than 1% ACG ointe inoculated ment allows improved treatment of epithelial SV-1-P) and lesions produced by highly resistant virus. ,V-1-P-ACGIsolation of virus from rabbit corneas then treated after ACG treatment. One rabbit from each of iment 1, the the two experiments described above was sethe resistant lected for viral culture. These were animals ich were al-which (i) had been inoculated with the original atment with Patton strain of virus, (ii) which had obvious rerage lesion corneal lesions, and (iii) which had been treated -treated and with ACG. Approximately 2 days were allowed uced by the after treatment had ceased before viral cultures e same ACG were taken. Cultures were taken by gently strok--and drug-ing a dry cotton swab across the cornea. Virus and 1.8, re-was readily isolated from both animals, allowed to produce 3 to 4+ cytopathic effects in human d so as (i) to fibroblast cells, aliquoted, and frozen at -70°C. ii) to use 3% Both strains were then titrated, and ED50 deterresults are minations were done on each isolate and the the lesions original Patton strain. In both cases, the virus recovered from the ACG-treated eyes was about three times more resistant to ACG (EDwo's were three times greater in simultaneous assays) than G/-R\ the virus originally inoculated. More importantly, it is clear that 6 days of treatment with ACG at concentrations of either 1 or 3% did not 27 \ lead to complete elimination of infectious virus from the eyes.
Susceptibility of ACG-resistant virus to o000 0000 Ara-A and IUDR. HSV-1-P (the original strain) and HSV-1-P-ACG-R (ACG-resistant strain) were compared in their susceptibilities to offour differ-three drugs: ACG, Ara-A, and IUDR. Table 2 ,in differences shows their EDro's and the calculated fold increase in resistance of the HSV-1-P-ACG-R strain to each drug (parent and resistant strains were titrated simultaneously in each experiment). The HSV-1-P-ACG-R strain was extremely resistant to ACG (as already demonstrated), unchanged in susceptibility to Ara-A, and parially resistant to IUDR (4.2-fold), when compared with its parent strain. Susceptibility of IUDR-resistant virus to ACG. Since ACG-resistant virus was partially resistant to IUDR (Table 2) , we sought to determine whether, conversely, IUDR-resistant virus is resistant to ACG. An HSV-1 strain (HSV-1-P) was passaged several times through ever-increasing concentrationa of IUDR until a strain emerged whose plaques could form in the presence of 10 jug of IUDR per ml (it was 17 times more resistant than the parent strain). This strain (designated HSV-1-P-IUDR-R) was then tested to determine its susceptibility to ACG. The results (Fig. 5) indicate that IUDRresistant virus is markedly resistant to ACG, i.e., the HSV-1-P-IUDR-R strain was over 100 times more resistant to ACG than its parent strain, HSV-1-P, and showed no evidence of plaque 
DISCUSSION
We showed that 6 of 15 different herpesvirus strains (which consisted oftypes 1 and 2, 11 new isolates, and 4 old laboratory strains), initially (before drug exposure) had 1% or more infectious particles capable of forg plaques in the presence of 10 ,mol of ACG. Serial in vitro passage ofone ofthese strains through gradually increasing concentrations of ACG resulted in the emergence of a highly resistant strain (resistant to a high drug concentration administered in vivo. Three percent ACG, which is now being used in prelicensing clinical trials as a topical treatment for human herpes keratitis, is probably a wise choice ofconcentration for therapeutic purposes. It is fortunate that ACG demonstrates such low toxicity for delicate tissues (2), enabling clinicians to use high therapeutic concentrations of the drug without tissue damage.
ACG-resistant virus was partially resistant to IUDR, and IUDR-resistant virus was highly resistant to ACG. This cross-resistance pattern can probably be explained by the fact that the two drugs share a common mechanism of antiviral action, i.e., inhibition of HSV-coded thymidine kinase activity (3, 8) . IUDR has several mechanisms of action not shared by ACG, including incorporation into viral deoxyribonucleic acid (8) and interference with viral assembly (8, 13) , which explains why highly ACG-resistant HSV is only partially resistant to IUDR. Our present finding that Ara-A is highly effective against ACG-resistant virus in vitro (see Table  2 ), together with the report that Ara-A is effective in many patients resistant to IUDR treatment (10) 
